RESUMEN
The circadian clock orchestrates the co-ordinated rhythmicity of numerous metabolic pathways to anticipate daily and seasonal changes in energy demand. This vital physiological function is controlled by a set of individual clock components that are present in each cell of the body, and regulate each other as well as clock output genes. A key factor is the nuclear receptor, Rev-erbα, a transcriptional repressor which functions not only as a clock component but also as a modulator of metabolic programming in an array of tissues. This review explores the role of Rev-erbα in mediating this crosstalk between circadian rhythm and tissue-specific biological networks and its relevance to organismal physiology.
Asunto(s)
Proteínas CLOCK/metabolismo , Ritmo Circadiano , Miembro 1 del Grupo D de la Subfamilia 1 de Receptores Nucleares/metabolismo , Transcripción Genética , Relojes Biológicos/fisiología , HumanosRESUMEN
Circadian rhythms have evolved to anticipate metabolic needs across the 24-h light/dark cycle. This is accomplished by circadian expression of metabolic genes orchestrated by transcription factors through chromatin remodeling and histone modifications. Our recent genome-wide study on histone deacetylase 3 (HDAC3) in mouse liver provides novel insights into the molecular link between circadian rhythm and hepatic de novo lipogenesis. We found that liver-specific knockout of HDAC3 in adult mouse displays severe hepatic steatosis associated with enhanced de novo lipogenesis and increased expression of lipogenic genes. Genome-wide analysis (ChIP-seq) revealed a pronounced circadian pattern of HDAC3 occupancy on genes involved in lipid metabolism, which is inversely related to histone acetylation and RNA polymerase II recruitment at these sites. The cistromes of HDAC3 and its binding partner, nuclear receptor corepressor (NCoR), significantly overlap with that of Rev-erbα, a nuclear receptor directly involved in the core circadian machinery. Knockout of Rev-erbα in mouse also leads to hepatic steatosis and enhanced de novo lipogenesis. Collectively, these data suggest that the circadian epigenomic remodeling controlled by HDAC3, and largely directed by Rev-erbα, is essential for homeostasis of the lipogenic process in liver.
Asunto(s)
Ritmo Circadiano/genética , Epigenómica , Histona Desacetilasas/metabolismo , Lipogénesis/genética , Hígado/metabolismo , Animales , Cromatina/metabolismo , HumanosRESUMEN
The link between obesity and diabetes is strong as well as complex. Fat cells produce many circulating regulators of insulin sensitivity, including pro-inflammatory cytokines. In rodents, resistin is produced by adipose tissue, and is a significant regulator of glucose metabolism and insulin sensitivity. In humans, resistin is derived made mainly from macrophages. Given the emerging interrelationship between inflammation and metabolic disease, hyperresistinemia may be a biomarker, and/or a mediator, of metabolic and inflammatory diseases in humans as well as in rodents.
Asunto(s)
Enfermedades Metabólicas/etiología , Obesidad/complicaciones , Resistina/fisiología , Tejido Adiposo/fisiología , Animales , Animales Modificados Genéticamente , Diabetes Mellitus Tipo 2/complicaciones , Sistema Endocrino/fisiología , Humanos , Inflamación/complicaciones , Resistencia a la Insulina/genética , Resistencia a la Insulina/fisiología , PPAR gamma/genética , PPAR gamma/fisiología , Resistina/genética , Roedores , Transducción de Señal/genética , Enfermedades Vasculares/etiología , Enfermedades Vasculares/genéticaRESUMEN
Repression of gene transcription is linked to regulation of chromatin structure through deacetylation of core histone amino-terminal tails. This action is mediated by histone deacetylases (HDACs) that function within active multiprotein complexes directed to the promoters of repressed genes. In vivo, HDAC3 forms a stable complex with the SMRT corepressor. The SMRT-HDAC3 complex exhibits histone deacetylase activity, whereas recombinant HDAC3 is an inactive enzyme. Here we report that SMRT functions as an activating cofactor of HDAC3. In contrast, SMRT does not activate the class II HDAC4, with which it also interacts. Activation of HDAC3 is mediated by a deacetylase activating domain (DAD) that includes one of two SANT motifs present in SMRT. A cognate DAD is present in the related corepressor N-CoR, which can also activate HDAC3. Mutations in the DAD that abolish HDAC3 interaction also eliminate reconstitution of HDAC activity. Using purified components, the SMRT DAD is shown to be necessary and sufficient for activation of HDAC3. Moreover, the DAD is required both for HDAC3 to function enzymatically and for the major repression function of SMRT. Thus, SMRT and N-CoR do not serve merely as platforms for HDAC recruitment but function as an integral component of an active cellular HDAC3 enzyme.
Asunto(s)
Cromatina/genética , Proteínas de Unión al ADN/genética , Histona Desacetilasas/genética , Proteínas Represoras/genética , Secuencia de Aminoácidos , Animales , Línea Celular , Activación Enzimática/genética , Regulación de la Expresión Génica , Datos de Secuencia Molecular , Co-Represor 2 de Receptor NuclearRESUMEN
Valproic acid is widely used to treat epilepsy and bipolar disorder and is also a potent teratogen, but its mechanisms of action in any of these settings are unknown. We report that valproic acid activates Wntdependent gene expression, similar to lithium, the mainstay of therapy for bipolar disorder. Valproic acid, however, acts through a distinct pathway that involves direct inhibition of histone deacetylase (IC(50) for HDAC1 = 0.4 mm). At therapeutic levels, valproic acid mimics the histone deacetylase inhibitor trichostatin A, causing hyperacetylation of histones in cultured cells. Valproic acid, like trichostatin A, also activates transcription from diverse exogenous and endogenous promoters. Furthermore, valproic acid and trichostatin A have remarkably similar teratogenic effects in vertebrate embryos, while non-teratogenic analogues of valproic acid do not inhibit histone deacetylase and do not activate transcription. Based on these observations, we propose that inhibition of histone deacetylase provides a mechanism for valproic acid-induced birth defects and could also explain the efficacy of valproic acid in the treatment of bipolar disorder.
Asunto(s)
Anticonvulsivantes/farmacología , Antimaníacos/farmacología , Inhibidores de Histona Desacetilasas , Histona Desacetilasas/metabolismo , Teratógenos , Ácido Valproico/farmacología , Proteínas de Pez Cebra , Acetilación , Animales , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Línea Celular , Relación Dosis-Respuesta a Droga , Glucógeno Sintasa Quinasa 3 , Proteínas Fluorescentes Verdes , Histona Desacetilasa 1 , Histonas/metabolismo , Humanos , Ácidos Hidroxámicos/farmacología , Concentración 50 Inhibidora , Litio/farmacología , Proteínas Luminiscentes/metabolismo , Plásmidos/metabolismo , Regiones Promotoras Genéticas , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Transducción de Señal , Factores de Tiempo , Transcripción Genética , Transfección , Proteínas Wnt , XenopusRESUMEN
Resistin is a peptide hormone secreted by adipocytes. Cysteine residues comprise 11 of 94 (12%) amino acids in resistin. The arrangement of these cysteines is unique to resistin and its recently discovered family of tissue-specific secreted proteins, which have been independently termed resistin-like molecules (RELMs) and the FIZZ (found in inflammatory zone) family. Here we show that resistin is a disulfide-linked homodimer that can be converted to a monomer by reducing conditions. The intestine-specific RELM beta has similar characteristics. Remarkably, however, the adipose-enriched RELM alpha is a monomer under non-reducing conditions. We note that RELM alpha lacks a cysteine residue, closest to the cleaved N terminus, that is present in resistin and RELM beta in multiple species. Conversion of this cysteine to alanine abolishes dimerization of resistin. Thus, a single disulfide bond is necessary to connect two resistin subunits in a homodimer. The additional 10 cysteines most likely participate in intramolecular disulfide bonds that define the conserved structure of the family members. The monomeric nature of RELM alpha suggests structural and potentially functional divergence between resistin and this close family member.
Asunto(s)
Hormonas Ectópicas/química , Proteínas , Adipocitos/metabolismo , Secuencia de Aminoácidos , Cisteína , Dimerización , Péptidos y Proteínas de Señalización Intercelular , Datos de Secuencia Molecular , Factor de Crecimiento Nervioso , Conformación Proteica , ResistinaRESUMEN
The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-regulated nuclear receptor superfamily member. Liganded PPARgamma exerts diverse biological effects, promoting adipocyte differentiation, inhibiting tumor cellular proliferation, and regulating monocyte/macrophage and anti-inflammatory activities in vitro. In vivo studies with PPARgamma ligands showed enhancement of tumor growth, raising the possibility that reduced immune function and tumor surveillance may outweigh the direct inhibitory effects of PPARgamma ligands on cellular proliferation. Recent findings that PPARgamma ligands convey PPARgamma-independent activities through IkappaB kinase (IKK) raises important questions about the specific mechanisms through which PPARgamma ligands inhibit cellular proliferation. We investigated the mechanisms regulating the antiproliferative effect of PPARgamma. Herein PPARgamma, liganded by either natural (15d-PGJ(2) and PGD(2)) or synthetic ligands (BRL49653 and troglitazone), selectively inhibited expression of the cyclin D1 gene. The inhibition of S-phase entry and activity of the cyclin D1-dependent serine-threonine kinase (Cdk) by 15d-PGJ(2) was not observed in PPARgamma-deficient cells. Cyclin D1 overexpression reversed the S-phase inhibition by 15d-PGJ(2). Cyclin D1 repression was independent of IKK, as prostaglandins (PGs) which bound PPARgamma but lacked the IKK interactive cyclopentone ring carbonyl group repressed cyclin D1. Cyclin D1 repression by PPARgamma involved competition for limiting abundance of p300, directed through a c-Fos binding site of the cyclin D1 promoter. 15d-PGJ(2) enhanced recruitment of p300 to PPARgamma but reduced binding to c-Fos. The identification of distinct pathways through which eicosanoids regulate anti-inflammatory and antiproliferative effects may improve the utility of COX2 inhibitors.
Asunto(s)
Ciclina D1/metabolismo , Inhibidores de Crecimiento/metabolismo , Proteínas Nucleares/metabolismo , Prostaglandina D2/análogos & derivados , Proteínas Serina-Treonina Quinasas/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Factores de Transcripción/metabolismo , Sitios de Unión , División Celular , Ciclina D1/genética , Fase G1 , Regulación de la Expresión Génica/efectos de los fármacos , Inhibidores de Crecimiento/genética , Células HeLa , Humanos , Quinasa I-kappa B , Ligandos , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico Sintasa de Tipo II , Proteínas Nucleares/genética , Regiones Promotoras Genéticas , Prostaglandina D2/metabolismo , Prostaglandina D2/farmacología , Receptores Citoplasmáticos y Nucleares/genética , Elementos de Respuesta , Transactivadores/metabolismo , Factor de Transcripción AP-1/metabolismo , Factores de Transcripción/genética , Células Tumorales CultivadasRESUMEN
Ligand-dependent exchange of coactivators and corepressors is the fundamental regulator of nuclear hormone receptor (NHR) function. The interaction surfaces of coactivators and corepressors are similar but distinct enough to allow the ligand to function as a switch. Multiple NHRs share features that allow corepressor binding, and each of two distinct corepressors (N-CoR and SMRT) contains two similar CoRNR motifs that interact with NHRs. Here we report that the specificity of corepressor-NHR interaction is determined by the individual NHR interacting with specific CoRNR boxes within a preferred corepressor. First, receptors have distinct preferences for CoRNR1 versus CoRNR2. For example, the retinoic acid receptor binds CoRNR1, while RXR interacts almost exclusively with CoRNR2. Second, the NHR preference for N-CoR or SMRT is due to differences in CoRNR1 but not CoRNR2. Moreover, within a single corepressor, affinity for different NHRs is determined by distinct regions flanking CoRNR1. The highly specific determinants of NHR-corepressor interaction and preference suggest that repression is regulated by the permissibility of selected receptor-CoRNR-corepressor combinations. Interestingly, different NHR surfaces contribute to binding of CoRNR1 and CoRNR2, suggesting a model to explain corepressor binding to NHR heterodimers.
Asunto(s)
Proteínas de Unión al ADN , Receptores Citoplasmáticos y Nucleares/química , Receptores Citoplasmáticos y Nucleares/metabolismo , Secuencia de Aminoácidos , Cromo/metabolismo , Dimerización , Relación Dosis-Respuesta a Droga , Eliminación de Gen , Humanos , Ligandos , Modelos Moleculares , Datos de Secuencia Molecular , Miembro 2 del Grupo A de la Subfamilia 4 de Receptores Nucleares , Plásmidos/metabolismo , Pruebas de Precipitina , Unión Proteica , Conformación Proteica , Estructura Terciaria de Proteína , Proteínas Recombinantes de Fusión/metabolismo , Homología de Secuencia de Aminoácido , Factores de Transcripción/metabolismo , Técnicas del Sistema de Dos HíbridosRESUMEN
We have identified a family of resistin-like molecules (RELMs) in rodents and humans. Resistin is a hormone produced by fat cells. RELMalpha is a secreted protein that has a restricted tissue distribution with highest levels in adipose tissue. Another family member, RELMbeta, is a secreted protein expressed only in the gastrointestinal tract, particularly the colon, in both mouse and human. RELMbeta gene expression is highest in proliferative epithelial cells and is markedly increased in tumors, suggesting a role in intestinal proliferation. Resistin and the RELMs share a cysteine composition and other signature features. Thus, the RELMs together with resistin comprise a class of tissue-specific signaling molecules.
Asunto(s)
Hormonas Ectópicas/química , Péptidos y Proteínas de Señalización Intercelular , Familia de Multigenes , Proteínas , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Secuencia de Consenso , Células Epiteliales/metabolismo , Perfilación de la Expresión Génica , Hormonas Ectópicas/genética , Humanos , Mucosa Intestinal/metabolismo , Ratones , Datos de Secuencia Molecular , Factor de Crecimiento Nervioso , Especificidad de Órganos , Ratas , Resistina , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Transducción de Señal , Especificidad de la EspecieRESUMEN
Diabetes mellitus is a chronic disease that leads to complications including heart disease, stroke, kidney failure, blindness and nerve damage. Type 2 diabetes, characterized by target-tissue resistance to insulin, is epidemic in industrialized societies and is strongly associated with obesity; however, the mechanism by which increased adiposity causes insulin resistance is unclear. Here we show that adipocytes secrete a unique signalling molecule, which we have named resistin (for resistance to insulin). Circulating resistin levels are decreased by the anti-diabetic drug rosiglitazone, and increased in diet-induced and genetic forms of obesity. Administration of anti-resistin antibody improves blood sugar and insulin action in mice with diet-induced obesity. Moreover, treatment of normal mice with recombinant resistin impairs glucose tolerance and insulin action. Insulin-stimulated glucose uptake by adipocytes is enhanced by neutralization of resistin and is reduced by resistin treatment. Resistin is thus a hormone that potentially links obesity to diabetes.
Asunto(s)
Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus/etiología , Hormonas Ectópicas/fisiología , Hormonas/fisiología , Péptidos y Proteínas de Señalización Intercelular , Obesidad , Proteínas , Tiazolidinedionas , Células 3T3 , Adipocitos/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Cromosomas Humanos Par 19 , Clonación Molecular , ADN , Diabetes Mellitus/sangre , Diabetes Mellitus/metabolismo , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/metabolismo , Dieta , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Intolerancia a la Glucosa , Hormonas/genética , Hormonas/metabolismo , Hormonas Ectópicas/genética , Hormonas Ectópicas/metabolismo , Humanos , Hipoglucemiantes/farmacología , Antagonistas de Insulina , Resistencia a la Insulina , Masculino , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Factor de Crecimiento Nervioso , Pruebas de Neutralización , Resistina , Rosiglitazona , Transducción de Señal , Tiazoles/farmacologíaRESUMEN
Studies on mice lacking the peroxisome proliferator-activated receptor (PPAR) suggest that PPAR ligands reduce lipid accumulation in foamy macrophages, and may target other receptors. These findings warrant an in-depth investigation into the gene regulatory mechanisms of PPAR ligands, which are currently being developed as drugs to treat atherosclerosis and diabetes.
Asunto(s)
Fenómenos Fisiológicos Cardiovasculares , Receptores Citoplasmáticos y Nucleares/fisiología , Factores de Transcripción/fisiología , Animales , Antígenos CD36/metabolismo , Células Espumosas/metabolismo , Humanos , Ligandos , Lipoproteínas LDL/metabolismo , Ratones , Ratones Noqueados , Receptores Citoplasmáticos y Nucleares/genética , Receptores Citoplasmáticos y Nucleares/metabolismo , Factores de Transcripción/genética , Factores de Transcripción/metabolismoRESUMEN
OBJECTIVES: Previous research has demonstrated that ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARs) reduce inflammation in two different murine models of colitis. This study was designed to examine the potential efficacy of rosiglitazone, a ligand for the gamma subtype of PPARs, as a therapy for active ulcerative colitis. METHODS: Fifteen patients with mild to moderately active ulcerative colitis despite therapy with 5-aminosalicylic acid compounds were enrolled in an open-label study of rosiglitazone (4 mg b.i.d. p.o.) for 12 wk. Thirteen of 15 patients were receiving concomitant therapy with corticosteroids and/or immunomodulator medications. Disease activity was measured with the Disease Activity Index. RESULTS: After 12 wk of therapy, four patients (27%) had achieved clinical remission, of whom three (20%) also had an endoscopic remission. Four additional patients (27%) had a clinical response without achieving remission. Two patients were hospitalized with worsened disease activity, and one patient was withdrawn for nephrotic syndrome. CONCLUSIONS: These data suggest that ligands for the gamma subtype of PPARs may represent a novel therapy for ulcerative colitis. A double blind, placebo-controlled, randomized trial is warranted.
Asunto(s)
Colitis Ulcerosa/tratamiento farmacológico , Colitis Ulcerosa/fisiopatología , Receptores Citoplasmáticos y Nucleares/metabolismo , Tiazoles/metabolismo , Tiazoles/uso terapéutico , Tiazolidinedionas , Factores de Transcripción/metabolismo , Adulto , Anciano , Colitis Ulcerosa/patología , Colonoscopía , Femenino , Humanos , Ligandos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Inducción de Remisión , Rosiglitazona , Índice de Severidad de la Enfermedad , Tiazoles/efectos adversosRESUMEN
Nearly 40% of cases of acute myelogenous leukemia (AML) of the M2 subtype are due to a chromosomal translocation that combines a sequence-specific DNA binding protein, AML1, with a potent transcriptional repressor, ETO. ETO interacts with nuclear receptor corepressors SMRT and N-CoR, which recruit histone deacetylase to the AML1-ETO oncoprotein. SMRT-N-CoR interaction requires each of two zinc fingers contained in C-terminal Nervy homology region 4 (NHR4) of ETO. However, here we show that polypeptides containing NHR4 are insufficient for interaction with SMRT. NHR2 is also required for SMRT interaction and repression by ETO, as well as for inhibition of hematopoietic differentiation by AML1-ETO. NHR2 mediates oligomerization of ETO as well as AML1-ETO. Fusion of NHR4 polypeptide to a heterologous dimerization domain allows strong interaction with SMRT in vitro. These data support a model in which NHR2 and NHR4 have complementary functions in repression by ETO. NHR2 functions as an oligomerization domain bringing together NHR4 polypeptides that together form the surface required for high-affinity interaction with corepressors. As nuclear receptors also interact with corepressors as dimers, oligomerization may be a common mechanism regulating corepressor interactions.
Asunto(s)
Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/metabolismo , Proteínas Nucleares/metabolismo , Proteínas Proto-Oncogénicas , Proteínas Represoras/metabolismo , Factores de Transcripción/química , Factores de Transcripción/metabolismo , Sitios de Unión , Diferenciación Celular , Proteínas de Unión al ADN/genética , Dimerización , Hematopoyesis , Humanos , Co-Represor 1 de Receptor Nuclear , Co-Represor 2 de Receptor Nuclear , Fragmentos de Péptidos/química , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/metabolismo , Unión Proteica , Estructura Cuaternaria de Proteína , Estructura Terciaria de Proteína , Proteína 1 Compañera de Translocación de RUNX1 , Receptores Citoplasmáticos y Nucleares/metabolismo , Eliminación de Secuencia , Factores de Transcripción/genética , Transfección , Células U937 , Dedos de ZincAsunto(s)
Xenobióticos/metabolismo , Animales , Sistema Enzimático del Citocromo P-450/biosíntesis , Sistema Enzimático del Citocromo P-450/genética , Regulación Enzimológica de la Expresión Génica , Humanos , Ratones , Modelos Animales , Receptores Citoplasmáticos y Nucleares/metabolismo , Xenobióticos/toxicidadRESUMEN
The major transcriptional factors involved in the adipogenic process include proteins belonging to the CCAAT/enhancer binding protein family, peroxisome proliferator-activated receptor gamma, and adipocyte determination and differentiation dependent factor 1, also known as sterol regulatory element-binding protein 1. This process has been characterized with the aid of cell lines that represent various stages in the path of adipocyte commitment, ranging from pluripotent mesodermal fibroblasts to preadipocytes. Molecular analyses have led to a cascade model for adipogenesis based on timed expression of CCAAT/enhancer-binding proteins and peroxisome proliferator-activated receptor gamma. Gene targeting and transgenic-mouse technologies, which allow the manipulation of endogenous genes for these transcription factors, have also contributed to the understanding of adipogenesis. This review aims to integrate this information to gain an understanding of the transcriptional regulation of fat cell formation.
Asunto(s)
Adipocitos/metabolismo , Tejido Adiposo/crecimiento & desarrollo , Obesidad/fisiopatología , Factores de Transcripción/fisiología , Adipocitos/citología , Animales , Diferenciación Celular/genética , Línea Celular , Humanos , Ratones , Modelos MolecularesRESUMEN
RAR and AML1 transcription factors are found in leukemias as fusion proteins with PML and ETO, respectively. Association of PML-RAR and AML1-ETO with the nuclear corepressor (N-CoR)/histone deacetylase (HDAC) complex is required to block hematopoietic differentiation. We show that PML-RAR and AML1-ETO exist in vivo within high molecular weight (HMW) nuclear complexes, reflecting their oligomeric state. Oligomerization requires PML or ETO coiled-coil regions and is responsible for abnormal recruitment of N-CoR, transcriptional repression, and impaired differentiation of primary hematopoietic precursors. Fusion of RAR to a heterologous oligomerization domain recapitulated the properties of PML-RAR, indicating that oligomerization per se is sufficient to achieve transforming potential. These results show that oligomerization of a transcription factor, imposing an altered interaction with transcriptional coregulators, represents a novel mechanism of oncogenic activation.
Asunto(s)
Transformación Celular Neoplásica , Leucemia/genética , Proteínas de Neoplasias/metabolismo , Proteínas de Fusión Oncogénica/metabolismo , Factores de Transcripción/metabolismo , Subunidad alfa 2 del Factor de Unión al Sitio Principal , Histona Desacetilasas/metabolismo , Humanos , Leucemia/etiología , Leucemia Mieloide/etiología , Leucemia Mieloide/genética , Leucemia Promielocítica Aguda/etiología , Leucemia Promielocítica Aguda/genética , Proteínas Nucleares/metabolismo , Co-Represor 1 de Receptor Nuclear , Fragmentos de Péptidos/metabolismo , Unión Proteica , Estructura Cuaternaria de Proteína , Proteína 1 Compañera de Translocación de RUNX1 , Proteínas Represoras/metabolismo , Elementos de Respuesta , Transcripción Genética , TretinoinaRESUMEN
Thyroid hormone is essential for normal development, differentiation, and metabolic balance. Thyroid hormone action is mediated by multiple thyroid hormone receptor isoforms derived from two distinct genes. The thyroid hormone receptors belong to a nuclear receptor superfamily that also includes receptors for other small lipophilic hormones. Thyroid hormone receptors function by binding to specific thyroid hormone-responsive sequences in promoters of target genes and by regulating transcription. Thyroid hormone receptors often form heterodimers with retinoid X receptors. Heterodimerization is regulated through distinct mechanisms that together determine the specificity and flexibility of the sequence recognition. Amino-terminal regions appear to modulate thyroid hormone receptor function in an isoform-dependent manner. Unliganded thyroid hormone receptor represses transcription through recruitment of a corepressor complex, which also includes Sin3A and histone deacetylase. Ligand binding alters the conformation of the thyroid hormone receptor in such a way as to release the corepressor complex and recruit a coactivator complex that includes multiple histone acetyltransferases, including a steroid receptor family coactivator, p300/CREB-binding protein-associated factor (PCAF), and CREB binding protein (CBP). The existence of histone-modifying activities in the transcriptional regulatory complexes indicates an important role of chromatin structure. Stoichiometric, structural, and sequence-specific rules for coregulator interaction are beginning to be understood, as are aspects of the tissue specificity of hormone action. Moreover, knockout studies suggest that the products of two thyroid hormone receptor genes mediate distinct functions in vivo. The increased understanding of the structure and function of thyroid hormone receptors and their interacting proteins has markedly clarified the molecular mechanisms of thyroid hormone action.
Asunto(s)
Hormonas Tiroideas/fisiología , Animales , Regulación de la Expresión Génica/genética , Regulación de la Expresión Génica/fisiología , Humanos , Receptores de Hormona Tiroidea/genética , Receptores de Hormona Tiroidea/fisiología , Hormonas Tiroideas/genéticaRESUMEN
The corepressor SMRT mediates repression by thyroid hormone receptor (TR) as well as other nuclear hormone receptors and transcription factors. Here we report the isolation of a novel SMRT-containing complex from HeLa cells. This complex contains transducin beta-like protein 1 (TBL1), whose gene is mutated in human sensorineural deafness. It also contains HDAC3, a histone deacetylase not previously thought to interact with SMRT. TBL1 displays structural and functional similarities to Tup1 and Groucho corepressors, sharing their ability to interact with histone H3. In vivo, TBL1 is bridged to HDAC3 through SMRT and can potentiate repression by TR. Intriguingly, loss-of-function TRbeta mutations cause deafness in mice and humans. These results define a new TR corepressor complex with a physical link to histone structure and a potential biological link to deafness.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Pérdida Auditiva Sensorineural/genética , Histona Desacetilasas/metabolismo , Proteínas Nucleares , Proteínas Represoras/metabolismo , Proteínas de Saccharomyces cerevisiae , Transducina/genética , Transducina/metabolismo , Secuencia de Aminoácidos , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico , Línea Celular , Cromatografía de Afinidad , Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/genética , Proteínas Fúngicas/química , Células HeLa , Histona Desacetilasas/química , Histona Desacetilasas/genética , Humanos , Ratones , Datos de Secuencia Molecular , Co-Represor 2 de Receptor Nuclear , Fragmentos de Péptidos/química , Fragmentos de Péptidos/inmunología , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Secuencias Repetitivas de Aminoácido , Proteínas Represoras/química , Proteínas Represoras/genética , Transducina/química , TransfecciónRESUMEN
Transcriptional activation requires both access to DNA assembled as chromatin and functional contact with components of the basal transcription machinery. Using the hormone-bound vitamin D(3) receptor (VDR) ligand binding domain (LBD) as an affinity matrix, we previously identified a novel multisubunit coactivator complex, DRIP (VDR-interacting proteins), required for transcriptional activation by nuclear receptors and several other transcription factors. In this report, we characterize the nuclear receptor binding features of DRIP205, a key subunit of the DRIP complex, that interacts directly with VDR and thyroid hormone receptor in response to ligand and anchors the other DRIP subunits to the nuclear receptor LBD. In common with other nuclear receptor coactivators, DRIP205 interaction occurs through one of two LXXLL motifs and requires the receptor's AF-2 subdomain. Although the second motif of DRIP205 is required only for VDR binding in vitro, both motifs are used in the context of an retinoid X receptor-VDR heterodimer on DNA and in transactivation in vivo. We demonstrate that both endogenous p160 coactivators and DRIP complexes bind to the VDR LBD from nuclear extracts through similar sequence requirements, but they do so as distinct complexes. Moreover, in contrast to the p160 family of coactivators, the DRIP complex is devoid of any histone acetyltransferase activity. The results demonstrate that different coactivator complexes with distinct functions bind to the same transactivation region of nuclear receptors, suggesting that they are both required for transcription activation by nuclear receptors.